“… n = 100 | Intravenous drug abuse, infectious metastases, purulent vein inflammation, endocarditis | | 6 | [ 85 ] | 20–40/F |
Streptococcus pneumoniae | n = 55 | | Amoxicillin, clarithromycin, azithromycin, ceftriaxone, ceftibuten, cefaclor | | [ 86 ] |
0–5 years |
Streptococcus pneumoniae | n = 71 | HIV | Third-generation cephalosporins, vancomycin, or erythromycin | 28 % | [ 87 ] |
42/M |
Streptococcus spp. | n = 522 | | | | [ 88 ] |
Viridans group Streptococcus | n = 79 (88 episodes) | Leukemia/stem cell transplantation | Piperacillin and gentamicin, piperacillin and tobramycin, or ceftazidime and tobramycin | | [ 89 ] |
<18 years of age | The most often used empiric therapy: piperacillin and tobramycin (75 % of episodes) |
Streptococcus agalactiae | 21 days/F | | Ceftriaxone | N | [ 90 ] |
Streptococcus anginosus | 46/M | Uremia, hypertension, recurrent infections | Ceftriaxone, vancomycin | N | [ 91 ] |
Streptococcus viridans | n = 15 | Hematological cancers | | | [ 92 ] |
<20 year of age |
Streptococcus spp. (in addition to S. pneumoniae ) | n = 30 | Community-acquired infections | | 3 | [ 93 ] |
59 years (average) |
15/M | ...
…”